These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30665388)

  • 1. The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.
    Gubbiotti M; Giannantoni A; Cantaluppi S; Coluccia AC; Ghezzi F; Serati M
    BMC Urol; 2019 Jan; 19(1):7. PubMed ID: 30665388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
    Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
    BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.
    Illiano E; Finazzi Agrò E; Natale F; Balsamo R; Costantini E
    Int Urol Nephrol; 2020 Jun; 52(6):1035-1042. PubMed ID: 32086713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.
    Zachariou A; Mamoulakis C; Filiponi M; Dimitriadis F; Giannakis J; Skouros S; Tsounapi P; Takenaka A; Sofikitis N
    BMC Urol; 2018 Jun; 18(1):61. PubMed ID: 29940933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
    Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
    Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
    Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
    Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome.
    Musco S; Serati M; Lombardi G; Lumi E; Parisi AI; Del Popolo G; Finazzi Agrò E
    J Sex Med; 2016 Feb; 13(2):238-42. PubMed ID: 26803455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
    Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
    BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?
    Balachandran A; Curtiss N; Basu M; Duckett J
    Int Urogynecol J; 2015 Mar; 26(3):367-72. PubMed ID: 25030325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
    Yamaguchi O; Marui E; Igawa Y; Takeda M; Nishizawa O; Ikeda Y; Ohkawa S
    Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirabegron for the treatment of overactive bladder.
    Gras J
    Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
    Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
    Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
    Chapple C; Khullar V; Nitti VW; Frankel J; Herschorn S; Kaper M; Blauwet MB; Siddiqui E
    Eur Urol; 2015 Jan; 67(1):11-14. PubMed ID: 25092537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction?
    Juliato CRT; Melotti IGR; Junior LCS; Britto LGO; Riccetto CLZ
    J Sex Med; 2017 Jul; 14(7):904-909. PubMed ID: 28622875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
    Balzarro M; Rubilotta E; Braga A; Bassi S; Processali T; Artibani W; Serati M
    Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.